Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
Status:
Active, not recruiting
Trial end date:
2021-07-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well cobimetinib and atezolizumab work in treating
participants with rare tumors that have spread to other places in the body (advanced) or that
does not respond to treatment (refractory). Cobimetinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal
antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and
may interfere with the ability of tumor cells to grow and spread. Giving cobimetinib and
atezolizumab may work better in treating participants with advanced or refractory rare
tumors.